Edaravone Has No Established Role in Intracerebral Hemorrhage Management
Edaravone should NOT be used for spontaneous intracerebral hemorrhage (ICH), as it is FDA-approved exclusively for amyotrophic lateral sclerosis (ALS) and is not mentioned in current evidence-based ICH guidelines. 1
Guideline-Based Recommendations
The most recent and authoritative guidelines for ICH management—the 2022 AHA/ASA guidelines 2 and 2014 ESO guidelines 3—make no mention of edaravone as a therapeutic option for intracerebral hemorrhage. These comprehensive guidelines address:
- Anticoagulation reversal strategies
- Blood pressure management
- Surgical interventions
- Intracranial pressure management
- Prevention of medical complications
The complete absence of edaravone from these guidelines is telling, particularly given that the 2022 AHA/ASA guideline 2 explicitly identifies therapies that should be avoided in ICH (prophylactic corticosteroids, continuous hyperosmolar therapy, platelet transfusions outside specific indications, prophylactic antiseizure medications).
FDA-Approved Indication
Edaravone injection is FDA-approved only for ALS treatment 1. The clinical trials supporting its approval involved ALS patients with specific functional criteria, not stroke or hemorrhage patients 1. Using edaravone for ICH would constitute off-label use without supporting evidence from adequately powered clinical trials.
Research Evidence Limitations
While several preclinical studies suggest potential mechanisms (anti-ferroptosis 4, anti-inflammatory effects 5, improved glucose metabolism 6), these are animal studies that have not translated to human clinical benefit in ICH:
- A 2011 Cochrane review 7 of 10 RCTs (768 participants) found poor quality evidence with no significant reduction in death (RR 0.93,95% CI 0.20-4.32 at 3 months) and no improvement in activities of daily living
- The review noted that all studies used routine care (not placebo) as controls, lacked blinding, and did not report the primary outcome of death or dependency at long-term follow-up
- While neurological impairment scores improved during treatment (RR 1.48,95% CI 1.29-1.69), it remains unclear whether this translates to clinically meaningful long-term benefit
Recent studies on edaravone dexborneol (a combination formulation) show promise in ischemic stroke 8, 9, but these findings cannot be extrapolated to hemorrhagic stroke, which has fundamentally different pathophysiology.
Clinical Bottom Line
For spontaneous intracerebral hemorrhage, focus on evidence-based interventions outlined in current guidelines 2:
- Immediate anticoagulation reversal when applicable (PCC for warfarin, idarucizumab for dabigatran, andexanet alfa for factor Xa inhibitors)
- Blood pressure management per protocol
- Minimally invasive surgical approaches for appropriate candidates (demonstrated mortality reduction)
- Cerebellar hemorrhage >15 mL warrants consideration of surgical evacuation
- Avoid therapies shown to be harmful or ineffective (platelet transfusions, prophylactic corticosteroids, graduated compression stockings alone)
Edaravone has no role in this treatment algorithm and should not be used for intracerebral hemorrhage outside of properly designed clinical trials.